コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 f A. elegans invasive fungal infection in an immunocompromised patient.
2 lgae that may cause serious infection in the immunocompromised patient.
3 emia associated with a G2576T mutation in an immunocompromised patient.
4 bolic or malignant diseases, particularly in immunocompromised patients.
5 capable of causing bacteremia and sepsis in immunocompromised patients.
6 devastating human diseases, particularly in immunocompromised patients.
7 hospital-acquired pneumonia and a killer of immunocompromised patients.
8 evious studies on hepatitis A vaccination in immunocompromised patients.
9 us PCR assay by using BAL fluid samples from immunocompromised patients.
10 rtant cause of morbidity and mortality among immunocompromised patients.
11 and disappointing results in the elderly and immunocompromised patients.
12 seudomonas aeruginosa in cystic fibrosis and immunocompromised patients.
13 lly untreatable cryptosporidial infection in immunocompromised patients.
14 nificant cause of morbidity and mortality in immunocompromised patients.
15 rasite of clinical importance, especially in immunocompromised patients.
16 nd Asia that can infect humans, particularly immunocompromised patients.
17 tly become a significant clinical problem in immunocompromised patients.
18 care and subspecialty providers who care for immunocompromised patients.
19 a life-threatening infection that occurs in immunocompromised patients.
20 ncluding Kaposi's sarcoma, commonly found in immunocompromised patients.
21 be an alternative approach, particularly for immunocompromised patients.
22 patitis E virus (HEV) can chronically infect immunocompromised patients.
23 teritis worldwide and can chronically infect immunocompromised patients.
24 V13-emergent serotypes are more prevalent in immunocompromised patients.
25 monary tuberculosis and the risk of death in immunocompromised patients.
26 nally reported to cause severe infections in immunocompromised patients.
27 hepatitis in healthy individuals as well as immunocompromised patients.
28 e considered in fresh produce selections for immunocompromised patients.
29 life-threatening toxoplasmic encephalitis in immunocompromised patients.
30 nital infection and causes severe disease in immunocompromised patients.
31 for drug-resistant strains, particularly in immunocompromised patients.
32 that causes severe, often fatal pneumonia in immunocompromised patients.
33 fungus recently recognized as a pathogen of immunocompromised patients.
34 monitoring treatment response, especially in immunocompromised patients.
35 for diagnosing LTBI, has reduced accuracy in immunocompromised patients.
36 accurately define the usefulness of IGRAs in immunocompromised patients.
37 ential treatment strategy in both normal and immunocompromised patients.
38 icant cause of morbidity and mortality among immunocompromised patients.
39 eased the detection of reemerging viruses in immunocompromised patients.
40 the predominant airborne fungal pathogen in immunocompromised patients.
41 own their safety in both immunocompetent and immunocompromised patients.
42 trol strategies should recommend vaccinating immunocompromised patients.
43 cause significant morbidity and mortality in immunocompromised patients.
44 y in our most vulnerable pediatric and adult immunocompromised patients.
45 espiratory viral pathogens in this cohort of immunocompromised patients.
46 serious causes of morbidity and mortality in immunocompromised patients.
47 portant cause of disease in hospitalized and immunocompromised patients.
48 n can cause severe pathology in children and immunocompromised patients.
49 es (IMDs) of the lung remain a challenge for immunocompromised patients.
50 onsidered an opportunistic human pathogen in immunocompromised patients.
51 xico, but not in blood or urine samples from immunocompromised patients.
52 ily involves prosthetic joints and occurs in immunocompromised patients.
53 sis (IA) is a life-threatening infection for immunocompromised patients.
54 nates to the CNS causing fatal meningitis in immunocompromised patients.
55 enteric and systemic diseases in normal and immunocompromised patients.
56 cussing the benefits and safety profile with immunocompromised patients.
57 s, particularly affecting critically ill and immunocompromised patients.
58 l antifungal vaccine strategies effective in immunocompromised patients.
59 for controlling chronic virus infections in immunocompromised patients.
60 with substantial morbidity and mortality in immunocompromised patients.
61 rapid and accurate identification of IPA in immunocompromised patients.
62 merged as a cause of chronic hepatitis among immunocompromised patients.
63 al pathogen that infects cystic fibrosis and immunocompromised patients.
64 isseminated infections that can be lethal in immunocompromised patients.
65 mportant cause of morbidity and mortality in immunocompromised patients.
66 cause of congenital disease and infection in immunocompromised patients.
67 um) in children and pure red cell aplasia in immunocompromised patients.
68 the safety of rotavirus vaccine in severely immunocompromised patients.
69 ive disseminated infections, particularly in immunocompromised patients.
70 s serious and frequently fatal infections in immunocompromised patients.
71 is the most common opportunistic disease in immunocompromised patients.
72 most common viral opportunistic infection in immunocompromised patients.
73 d management of influenza virus infection in immunocompromised patients.
74 individuals but can cause severe disease in immunocompromised patients.
75 ctions in humans are rare and usually affect immunocompromised patients.
76 opportunistic pathogen that commonly infects immunocompromised patients.
77 act infections in children, the elderly, and immunocompromised patients.
78 reatening systemic bloodstream infections in immunocompromised patients.
79 , and how this mechanism might break down in immunocompromised patients.
80 infect airways of cystic fibrosis and other immunocompromised patients.
81 onas aeruginosa causes serious infections in immunocompromised patients.
82 ian hamsters that is similar to that seen in immunocompromised patients.
83 s (IPA) is one of the major complications in immunocompromised patients.
84 herpesvirus-8) is frequently tumorigenic in immunocompromised patients.
85 s known to cause rapidly fatal infections in immunocompromised patients.
86 major cause of fungal meningoencephalitis in immunocompromised patients.
87 severe organ and life-threatening disease in immunocompromised patients.
88 umans and an important cause of mortality in immunocompromised patients.
89 te with the potential to cause bacteremia in immunocompromised patients.
90 ogen that poses significant health risks for immunocompromised patients.
91 uses life-threatening meningoencephalitis in immunocompromised patients.
92 HCT recipients and perhaps in other severely immunocompromised patients.
93 g life-threatening invasive aspergillosis in immunocompromised patients.
94 iviral drugs has been described primarily in immunocompromised patients.
95 lbicans is a major opportunistic pathogen in immunocompromised patients.
96 ajor, global cause of meningoencephalitis in immunocompromised patients.
97 (PcP) is a clinically important infection of immunocompromised patients.
98 were shown to cause significant morbidity to immunocompromised patients.
99 threatening infection that usually occurs in immunocompromised patients.
100 Four of 6 infections occurred in immunocompromised patients.
101 istic pathogen that causes severe disease in immunocompromised patients.
102 hodotorula species are emerging pathogens in immunocompromised patients.
103 al pathogen known to cause severe disease in immunocompromised patients.
104 mportant cause of morbidity and mortality in immunocompromised patients.
105 se resembling human adenovirus infections in immunocompromised patients.
106 ting disease in nearly every organ system in immunocompromised patients.
107 sponsible for deadly, invasive infections in immunocompromised patients.
108 e of serious human infections, especially in immunocompromised patients.
109 in a larger cohort including non-hematologic immunocompromised patients.
110 uences, infection can be life threatening in immunocompromised patients.
111 s that causes severe disease in newborns and immunocompromised patients.
112 tunistic pathogens and can pose a threat for immunocompromised patients.
113 y prevalent health problem, especially among immunocompromised patients.
114 rus JC virus, which typically occurs only in immunocompromised patients.
115 enotype 3 may result in chronic hepatitis in immunocompromised patients.
116 iratory disease in infants, the elderly, and immunocompromised patients.
117 fe-threatening syndrome that often occurs in immunocompromised patients.
118 oformans is a significant fungal pathogen of immunocompromised patients.
119 d to life-threatening meningoencephalitis in immunocompromised patients.
120 for the treatment of chronic hepatitis E in immunocompromised patients.
121 viduals and for a severe invasive disease in immunocompromised patients.
122 f infectious diseases in transplantation and immunocompromised patients.
123 encephalitis is particularly challenging in immunocompromised patients.
124 enza vaccine immunogenicity is suboptimal in immunocompromised patients.
125 ing cutaneous and subcutaneous infections in immunocompromised patients.
126 pneumonia (Pneumocystis pneumonia [PcP]) in immunocompromised patients.
127 nocardiosis and compared immunocompetent and immunocompromised patients.
128 causes potentially fatal bacteremia in some immunocompromised patients.
129 nd a significant health risk, especially for immunocompromised patients.
130 VZV-infected brains obtained at autopsy from immunocompromised patients.
131 in gravest danger: malnourished children and immunocompromised patients.
132 y among vulnerable populations, particularly immunocompromised patients.
133 y illness in young infants, the elderly, and immunocompromised patients.
134 is an opportunistic pathogen that can infect immunocompromised patients.
135 nd it can cause life-threatening diseases in immunocompromised patients.
136 is uncertainty about their immunogenicity in immunocompromised patients.
137 with intravenous acyclovir therapy given to immunocompromised patients (10 mg/kg every 8 h for 7 day
138 We collected 90 respiratory samples from 87 immunocompromised patients (56 bronchoalveolar lavage an
143 istance to oseltamivir were isolated from an immunocompromised patient after prolonged oseltamivir tr
145 es recommend annual influenza vaccination of immunocompromised patients, although the decision to vac
146 fection with Neoscytalidium dimidiatum in an immunocompromised patient and discuss in vitro susceptib
147 Disseminated Oka VZV was identified in 6 immunocompromised patients and 1 patient with Down syndr
148 pital policies for safe food preparation for immunocompromised patients and by not serving them highe
149 al drugs emerges with increased frequency in immunocompromised patients and can limit the benefit of
150 esponses have been extensively documented in immunocompromised patients and during in utero acquisiti
151 associated with life-threatening diseases in immunocompromised patients and in otherwise healthy indi
152 th nonmelanoma skin cancers, particularly in immunocompromised patients and individuals with a rare g
153 fungal infection that predominantly affects immunocompromised patients and is uniformly fatal if lef
154 known to induce vasoproliferative tumors in immunocompromised patients and may play a role in the de
155 infection is increasingly being reported in immunocompromised patients and particularly organ transp
156 ether these new strains are of risk to other immunocompromised patients and the general population.
157 sent an emerging problem during treatment of immunocompromised patients and those hospitalized with s
158 c pathogen that causes serious infections in immunocompromised patients and those with cystic fibrosi
159 rogressive mental deterioration in an older, immunocompromised patient, and even though Koch's postul
160 of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability
161 s one of the leading causes of infections in immunocompromised patients, and innate immunity provides
163 ls, in part because sepsis normally involves immunocompromised patients, and massive lymphocyte apopt
164 and complement fixation, is not impaired in immunocompromised patients, and permits highly reproduci
165 HAstV 1-8, are neuropathic, particularly in immunocompromised patients, and should be considered in
168 hat can cause life-threatening infections in immunocompromised patients, and we now present data on a
170 enza pneumonia has not been established, and immunocompromised patients are highly susceptible to eme
171 pre-existing pulmonary lesions, and severely immunocompromised patients are susceptible to develop in
174 tococcus neoformans, a yeast that can affect immunocompromised patients as an opportunistic pathogen.
175 ety of hospital-acquired acute infections in immunocompromised patients as well as chronic respirator
176 lated bacteria that cause lung infections in immunocompromised patients as well as in patients with g
177 ve vaccine efficacy in infants, the elderly, immunocompromised patients, as well as healthy adults.
178 ryptococcal meningitis has been described in immunocompromised patients, as well as in those for whom
179 or acute cardiogenic pulmonary edema, and in immunocompromised patients, as well as to facilitate ext
181 is in healthy children and severe disease in immunocompromised patients but has not been previously r
182 ssociated with a variety of complications in immunocompromised patients, but no studies have systemat
183 ntral to the management of CMV infections in immunocompromised patients, but quantitative results cur
184 MV) or Epstein-Barr virus (EBV) infection in immunocompromised patients can be treated by adoptive tr
186 bacteria across the intestinal epithelium of immunocompromised patients can lead to bacteremia and li
188 rugs for the treatment of HAdV infections in immunocompromised patients continues to be a challenging
190 fections, chronic infections may occur among immunocompromised patients (e.g., transplant recipients
192 ytogenes, a food-borne pathogen that infects immunocompromised patients, enters and proliferates with
194 been recognized as an important pathogen of immunocompromised patients, especially patients infected
195 known for its propensity to cause disease in immunocompromised patients, especially transplant recipi
197 aumannii, which causes serious infections in immunocompromised patients, expresses high-affinity iron
199 or relevance due to the increased numbers of immunocompromised patients, frequently delayed diagnosis
200 We document 3 cases of influenza in severely immunocompromised patients from whom virus variants with
201 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 years of age.
203 intravenous acyclovir therapy; in contrast, immunocompromised patients had improved outcomes and wou
206 s and treatment of other virus infections in immunocompromised patients; however, extension to subjec
209 -analysis assesses influenza vaccination for immunocompromised patients in terms of preventing influe
210 (IA) remains a leading cause of mortality in immunocompromised patients, in part due to the difficult
211 sent potentially important considerations in immunocompromised patients, in particular in organ trans
212 decreased sensitivity may be problematic for immunocompromised patients, in whom low levels of HAdV i
213 is an emerging fungal pathogen that infects immunocompromised patients including HIV/AIDS, cancer, a
214 illus fumigatus, which is a major threat for immunocompromised patients, including allogeneic hematop
215 y, mainly due to an increasing population of immunocompromised patients, including individuals with H
217 are associated with substantial morbidity in immunocompromised patients, including those with HIV/AID
218 HHV-8 and its clinical disease is highest in immunocompromised patients, including transplant recipie
219 neuraminidase H275Y mutation collected from immunocompromised patients infected with pandemic influe
220 in immunocompetent individuals, their use in immunocompromised patients is complicated by the develop
222 major challenge in treating toxoplasmosis in immunocompromised patients is lack of therapeutic agents
226 associated smooth muscle tumors are found in immunocompromised patients, most commonly HIV/AIDS.
227 ative to TIV, but the safety of this LAIV in immunocompromised patients must first be established.
230 zed trial conducted among 374 critically ill immunocompromised patients, of whom 317 (84.7%) were rec
231 se of nosocomial infections, particularly in immunocompromised patients or in individuals with cystic
232 exclusively in hospitals and were limited to immunocompromised patients or individuals with predispos
233 pathogens represent a significant threat to immunocompromised patients or individuals with traumatic
235 esting to specific groups of patients (e.g., immunocompromised patients), or providing education to e
236 ne included diverse racial groups, children, immunocompromised patients, or individuals who received
237 to first surgical procedure were delayed in immunocompromised patients (P < .001 and P = .001, respe
239 nt contributor to morbidity and mortality in immunocompromised patients, particularly in the transpla
240 and often fatal, disease (cryptococcosis) in immunocompromised patients, particularly in those with H
241 a major cause of morbidity and mortality in immunocompromised patients, particularly those infected
242 elderly men, pregnant women, young children, immunocompromised patients, patients with preexisting li
243 acterial compounds that are commonly used in immunocompromised patients, piperacillin-tazobactam expr
246 e a standard part of care for many groups of immunocompromised patients; recent development of the fi
247 ns following respiratory viral infections in immunocompromised patients remain crucial for reducing t
250 gene deletion was rapidly selected for in an immunocompromised patient, resulting in decreased sensit
251 microbial therapy for babesiosis in severely immunocompromised patients should be extended to 6 weeks
253 pathogen that causes respiratory illness in immunocompromised patients, such as those with cystic fi
254 biota, as well as the unique epidemiology of immunocompromised patients that renders them a particula
255 nating disease of the white matter affecting immunocompromised patients that results from the cytolyt
256 nce surveillance is highly recommended among immunocompromised patients to manage the clinical syndro
257 A systematic visit in a travel clinic for immunocompromised patients traveling to the tropics ensu
258 s well as the threats of viral infections in immunocompromised patients, underline our efforts to cha
259 a significant cause of disease and death in immunocompromised patients, underscoring the need to und
260 d-glucan determined in 70 serum samples from immunocompromised patients were compared to fungal load
265 rmans frequently causes fungal meningitis in immunocompromised patients, whereas the related species
266 the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency t
267 cologically widespread and affects primarily immunocompromised patients, while C. gattii is tradition
269 ents have significantly improved outcomes in immunocompromised patients who develop invasive aspergil
271 adverse events have been reported, mainly in immunocompromised patients who subsequently recovered.
274 ith EORTC/MSG criteria for diagnosing IFD in immunocompromised patients with a high degree of antifun
276 r to be of particular importance in severely immunocompromised patients with advanced neoplastic dise
277 minimum of 6 weeks of antibiotics for highly immunocompromised patients with babesiosis, with no para
278 okine for systemic C. albicans infections in immunocompromised patients with cancer or advanced acqui
280 ificantly improved with antiviral therapy in immunocompromised patients with herpes meningitis (P < .
285 of noninvasive ventilation in critically ill immunocompromised patients with hypoxemic acute respirat
286 The objective was to assess outcomes of immunocompromised patients with hypoxemic acute respirat
287 been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respirat
290 deep-sequence longitudinal samples from four immunocompromised patients with long-term H3N2 influenza
293 asibility of developing an immunotherapy for immunocompromised patients with uncontrolled infections.
294 Practice-compliant manufacturing process, in immunocompromised patients with uncontrolled infections.
295 uenza, patients with RSV were older and more immunocompromised; patients with HMPV were older, had mo
296 at often causes lung and brain infections in immunocompromised patients, with a high fatality rate.
297 s the spectrum of EBV(+)diseases, even among immunocompromised patients, with plasma specimens more i
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。